Umeclidinium bromide

Umeclidinium bromide (UMEC) is an anticholinergic drug used in the treatment of chronic obstructive pulmonary disease (COPD). It is a long-acting muscarinic antagonist (LAMA) that works by blocking the action of the neurotransmitter acetylcholine on certain receptors in the lungs, thereby leading to bronchodilation. UMEC is sold under the brand name Incruse Ellipta and is typically used as a once-daily inhalation treatment for COPD. It is available in both a dry powder inhaler and a pressurized metered dose inhaler.

Umeclidinium bromide is a medication used to treat chronic obstructive pulmonary disease (COPD). Here's a breakdown of its key points:

• Brand Name: Incruse Ellipta
• Drug Class: Long-acting muscarinic antagonist (LAMA)
• Use: Maintenance treatment for symptoms of COPD, such as wheezing, shortness of breath, coughing, and chest tightness.
• How it Works: Umeclidinium bromide relaxes the muscles around the airways in your lungs, making it easier to breathe.

Additional Information:

• Umeclidinium bromide is typically delivered through inhalation using a device called an Ellipta inhaler.
• It's a long-acting medication, meaning it provides relief for a full 24 hours with a single daily dose.
• Umeclidinium bromide is sometimes prescribed in combination with other COPD medications, like vilanterol or fluticasone furoate.